Skip to main content

Table 1 Summary of the published studies investigating the effect of therapeutic plasma exchange for COVID-19

From: Blood purification could tackle COVID-19?

Trials Study design Sample size (TPE/control) TPE replacement fluids Number of TPE treatment Results (mortality rate, MV, LOS)
Gucyetmez et al. [13] Retrospective study with PSM 12/12 Not mentioned Not mentioned ・ Mortality rate—mortality, 8% vs. 58%, p < 0.01
・ MV—duration of MV, 316 h vs. 278 h, p = 0.67
・LOS—ICU LOS, 20 days vs. 14 days, p = 0.07
Kamran et al. [14] Retrospective study with PSM 45/45 FFP: normal saline = 2:1 Daily until recovery ・Mortality rate—overall survival, 91% vs. 62%, p < 0.01
・ LOS—Total LOS, 10 days vs. 15 days, p = 0.01
Khamis et al. [15] Retrospective study 11/20 FFP 5 times ・ Mortality rate—all-cause mortality, 9% vs. 45%, p = 0.055
28 day mortality, 0% vs. 35%, p = 0.033
14 day mortality, 0% vs. 35%, p = 0.033
・ MV—extubation, 73% vs. 20%, p = 0.02
・ LOS—total LOS, 19 days vs. 11 days, p = 0.13
ICU LOS, 14 days vs. 6 days, p = 0.03
Faqihi et al. [16] RCT 34/39 FFP or artificial Ocyaplas LG® Maximum of 5 times ・ Mortality rate—35 day mortality, 21% vs. 34%, p = 0.09
・ MV—duration of MV, 15 days vs. 19 days, p < 0.01
・ LOS—ICU LOS, 19 days vs. 26 days, p = 0.02
  1. APACHE Acute Physiology and Chronic Health Evaluation, ARDS acute respiratory distress syndrome, FFP fresh frozen plasma, ICU intensive care unit, LOS length of stay, MDOS multiple organ dysfunction syndrome, MV mechanical ventilation, TPE therapeutic plasma exchange, PSM propensity score matching, RCT randomized controlled trial